Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

459.58 +44.24 (+10.65%)
Streaming Delayed Price Updated: 10:16 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 597,434
Open 415.37
Bid (Size) 457.16 (2)
Ask (Size) 462.00 (1)
Prev. Close 415.34
Today's Range 415.26 - 469.15
52wk Range 266.98 - 459.48
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short
Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
Via Investor's Business Daily
United Therapeutics Corp (NASDAQ:UTHR) Reports Q3 2025 Earnings: Revenue Misses, EPS Beats Estimates
United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue. 
Via Chartmill

Performance

YTD
+27.6%
+27.6%
1 Month
+8.3%
+8.3%
3 Month
+54.4%
+54.4%
6 Month
+52.8%
+52.8%
1 Year
+31.4%
+31.4%

More News

Read More
Earnings Scheduled For October 29, 2025
Via Benzinga
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings
Via StockStory
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
A Peek at United Therapeutics's Future Earnings
Via Benzinga
United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
Via MarketMinute
Topics Retirement
United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria
Via Chartmill
United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate
Via Chartmill
1 Value Stock for Long-Term Investors and 2 Facing Headwinds
Via StockStory
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
2 Growth Stocks with All-Star Potential and 1 Facing Headwinds
Via StockStory
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
1 Momentum Stock to Target This Week and 2 We Brush Off
Via StockStory
3 Big Reasons to Love United Therapeutics (UTHR)
Via StockStory
Topics Stocks
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment
Via Chartmill
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
Via Investor's Business Daily
Topics ETFs
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
Via Benzinga
United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals
Via Chartmill

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 459.58
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 10/29/25 10:16 AM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 20.63B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.